Bruce was co-inventor of Humalog and retired from Eli Lilly after 34-years in which he held several senior management positions in insulin discovery, development, manufacturing, and regulatory affairs. He received his Ph.D. in Physical Biochemistry from Northwestern and did his post-doc at Berkley.

Rick is a serial entrepreneur who has successfully launched and financed multiple life science and other organizations around important new technologies in complex markets. A former McKinsey consultant, Rick received a JD-MBA from Harvard Business and Law Schools in 1984 and is a graduate of Harvard College.

Expert on insulin analog design; currently Chairman, Biochemistry & Molecular Biology, Indiana University School of Medicine, >150 publications on insulin, 4 “Paper of the Week” in JBC. Former Chair of Biochemistry and Chair of NIDDK’s Board of Scientific Councilors. MD, summa cum laude & PhD in biophysics from Harvard.

CEO, Healthcare Capital, LLC; former CEO of Joslin Diabetes Center in Boston; founder of Prism Ventures; John serves on several life science and not-for-profit boards.

Thom is an accomplished researcher, who has driven development efforts in the biotech and biopharma sectors, including at Myriad Genetics, AmpliCon, and Cellular Technology. Thom earned a BA at Connecticut College; an MS in biochemistry, PhD in pathology, and completed post-doctoral work in molecular genetics, all at Case Western Reserve University.